Floatz logo

bnt162b2

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Massachusetts General HospitalvaccineDormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
dzd8586
Dizal Pharmaceuticals
Phase 3BB
Elsamitrucin
Spectrum Pharmaceuticals, Inc
Phase 2B
Evomela
City of Hope Medical Center
Phase 2B
psb202
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Phase 1CC
ad26.cov2.s
Massachusetts General Hospital
D
PCV 13
Massachusetts General Hospital
D

Same molecule, other indications

bnt162b2 is also rated in:

Multiple SclerosisDormant
CC
Indicative ·
44 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
43 / 100
View asset →
rheumatoid arthritisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →